Project description
Innovative injectable hydrogel for the treatment of osteoarthritis
Osteoarthritis (OA) is a long-term chronic disease associated with the deterioration of the cartilage in joints. Wear and tear is often the cause of OA in the elderly, while sports injuries and falls are the triggers of OA in younger patients. Hy2Care in the Netherlands developed a regenerative injectable hydrogel for damaged cartilage treatment. A one-time arthroscopy procedure using a syringe hydrogel injection fills the defects, preventing the ingrowth of scar tissue and allowing healing by creating cartilage with the optimal regenerated tissue. The EU-funded ACTIVE project aims to evaluate the safety and performance of Hy2Care technology for the repair of cartilage defects in the knee at selected medical centres in the Netherlands.
Objective
Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthroscopy. The hydrogel fill the defect, prevents ingrowth of scar tissue and allows the body to heal itself by creating true Hyaline cartilage, ensuring an optimal regenerated tissue. The high-quality regeneration provides the basis for a long lasting repair, postponing or even preventing the onset of osteoarthritis.
The gel binds covalently to the surrounding cartilage ensuring integration of the new tissue. Revalidation is fast as the cartilage regrowth follows the degradation of the gel. The lasting repair not only prevents additional secondary treatments but also pain, disability and escalating follow-on costs.
In submission of the last cut off of the EIC in october 2020 Hy2Care scored a 14.0 and recieved the seal of excellence.
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
6167 RD Geleen
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.